This is a preview of subscription content, log in via an institution to check access.
Notes
2014 US dollars
Reference
Jackman DM, et al. Cost and Survival Analysis Before and After Implementation of Dana-Farber Clinical Pathways for Patients With Stage IV Non-Small-Cell Lung Cancer. Journal of Oncology Practice : JOP2017021741, 4 Mar 2017
Rights and permissions
About this article
Cite this article
Clinical pathway cost saving in metastatic NSCLC. PharmacoEcon Outcomes News 774, 10 (2017). https://doi.org/10.1007/s40274-017-3834-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-3834-x